Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Health-related quality of life (HRQoL) outcomes in the RATIONALE-305 study.

被引：0

作者：

Cruz-Correa, Marcia

Xu, Rui-Hua

Moehler, Markus H.

Oh, Do-Youn

Kato, Ken

Spigel, David R.

Arkenau, Hendrik-Tobias

Tabernero, Josep

Zimina, Anastasia V.

Bai, Yuxian

Shi, Jianhua

Lee, Keun-Wook

Hirano, Hidekazu

Wyrwicz, Lucjan S.

Pazo Cid, Roberto

Xu, Hui

Sheng, Tao

Barnes, Gisoo

机构：

[1] Univ Puerto Rico, Sch Med, San Juan, PR 00936 USA

[2] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China

[3] Johannes Gutenberg Univ Clin, Dept Internal Med, Mainz, Germany

[4] Seoul Natl Univ Hosp, Dept Internal Med, Div Med Oncol, Seoul, South Korea

[5] Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea

[6] Natl Canc Ctr, Tokyo, Japan

[7] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA

[8] Sarah Cannon Res, London, England

[9] Vall DHebron Univ Hosp & Inst Oncol VHIO, Barcelona, Spain

[10] BHI Omsk Reg Clin Oncol Dispensary, Omsk, Russia

[11] Harbin Med Univ Canc Hosp, Dept Gastrointestinal Oncol, Harbin, Peoples R China

[12] Linyi Canc Hosp, Dept Med Oncol, Linyi, Peoples R China

[13] Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Seongnam, South Korea

[14] Natl Canc Ctr Hosp, Dept Gastrointestinal Med Oncol, Chuo City, Japan

[15] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[16] Hosp Univ Miguel Servet, Zaragoza, Spain

[17] BeiGene Beijing Co Ltd, Beijing, Peoples R China

[18] BeiGene USA Inc, San Mateo, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期

关键词：

261-566-148; 613-135-2370-7650-2700; 130-274-2403; 613-302-309; 613-302-312-303; 17; 9; 3; 2; 2424; 1704;

D O I：

10.1200/JCO.2024.42.3_suppl.290

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：290 / 290

页数：1

共 50 条

[41] Longitudinal ctDNA levels and clinical outcomes of first-line (1L) tislelizumab (TIS) plus chemotherapy (chemo) treatment for advanced non-small cell lung cancer (NSCLC) in the RATIONALE-304 and 307 studies
Lu, Shun
Wang, Jie
Sun, Meili
Zhao, Jun
Hu, Chunhong
Wang, Mengzhao
Zhou, Jianying
Song, Yong
Zhou, Qinghua
Zhang, Jiayuan
Shi, Yang
Huang, Ruiqi
Wu, Xikun
He, Wanyu
Qu, Xiaofei
Zhang, Yun
Shen, Zhirong
Yu, Yan
CANCER RESEARCH, 2023, 83 (08)
[42] RATIONALE 307: Tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC) in patients (pts) who were smokers vs non-smokers
Yu, X.
Wang, J.
Lu, S.
Zhao, J.
Yu, Y.
Hu, C.
Feng, G.
Ying, K.
Zhuang, W.
Zhou, J.
Wu, J.
Leaw, S. J.
Lin, X.
Zhang, J.
ANNALS OF ONCOLOGY, 2021, 32 : S1005 - S1005
[43] First-line nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 2-year follow-up
Shen, L.
Bai, Y.
Lin, X.
Li, W.
Wang, J.
Zhang, X.
Pan, H.
Bai, C.
Bai, L.
Cheng, Y.
Zhang, J.
Zhong, H.
Ba, Y.
Hu, W.
Xu, R.
Guo, W.
Qin, S.
Yang, N.
Lu, J.
Chanaga, C. Amaya
Soleymani, S.
Liu, T.
ANNALS OF ONCOLOGY, 2022, 33 : S279 - S279
[44] Cost-effectiveness of tislelizumab plus chemotherapy vs chemotherapy as first-line treatment of PD-L1 positive advanced gastric or gastroesophageal junction adenocarcinoma from a Chinese perspective
Li, Wei
Wan, Li
Zhang, Jiangyan
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2024, 18 (06) : 293 - 301
[45] Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: perspectives from the United States and China
Lang, Wenwang
Ai, Qi
Zhang, Wenwen
Jiang, Qinling
He, Yulong
Ouyang, Ming
FRONTIERS IN PHARMACOLOGY, 2024, 15
[46] Health-related quality of life (HRQoL) impact of lenvatinib (len) plus pembrolizumab (pembro) versus len plus placebo (pbo) as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC): Phase 3 LEAP-002 study.
Llovet, Josep M.
Kudo, Masatoshi
Merle, Philippe
Meyer, Tim
Qin, Shukui
Ikeda, Masafumi
Xu, Ruocai
Edeline, Julien
Ryoo, Baek-Yeol
Ren, Zhenggang
Cheng, Ann-Lii
Galle, Peter R.
Kaneko, Shuichi
Kumada, Hiromitsu
Kamble, Shital
Norquist, Josephine M.
Mody, Kalgi
Dubrovsky, Leonid
Siegel, Abby B.
Finn, Richard S.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 506 - 506
[47] Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.
Chau, Ian
Doki, Yuichiro
Ajani, Jaffer A.
Xu, Jianming
Wyrwicz, Lucjan
Motoyama, Satoru
Ogata, Takashi
Kawakami, Hisato
Hsu, Chih-Hung
Adenis, Antoine
El Hajbi, Farid
Di Bartolomeo, Maria
Freitas Melro Braghiroli, Maria Ignez
Holtved, Eva
Xynos, Ioannis
Liu, Xuan
Lei, Ming
Kondo, Kaoru
Kato, Ken
Kitagawa, Yuko
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (18)
[48] Phase (Ph) II study of zanidatamab plus chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA)
Ku, G.
Elimova, E.
Denlinger, C. S.
Mehta, R.
Lee, K-W.
Iqbal, S.
Kang, Y-K.
Oh, D-Y.
Rha, S. Y.
Kim, Y. H.
Seol, Y. M.
Mwatha, T.
Grim, J.
Ajani, J. A.
ANNALS OF ONCOLOGY, 2021, 32 : S1044 - S1045
[49] First-line (1L) tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 Japanese subgroup analysis with longer follow-up.
Kojima, Takashi
Ogata, Takashi
Ishihara, Ryu
Hara, Hiroki
Sun, Tianmo
Xu, Sheng
Kato, Ken
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 420 - 420
[50] AdvanTIG-105: A phase 1b dose-expansion study of ociperlimab (OCI) plus tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC)
Kim, Se Hyun
Lee, Gyeong-Won
Shim, Byoung Yong
Spigel, David R.
Shiah, Her-Shyong
Frentzas, Sophia
Yoon, Harry H.
Wang, Feng
Sun, Meili
Clay, Timothy Dudley
Zheng, Hao
Tan, Wei
Zhou, Ziqi
Wang, Ruihua
Ba, Yi
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →